4D Molecular Therapeutics (FDMT) Assets Average (2021 - 2025)
4D Molecular Therapeutics (FDMT) has disclosed Assets Average for 5 consecutive years, with $448.8 million as the latest value for Q3 2025.
- On a quarterly basis, Assets Average fell 26.67% to $448.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was $448.8 million, a 26.67% decrease, with the full-year FY2024 number at $450.1 million, up 49.61% from a year prior.
- Assets Average was $448.8 million for Q3 2025 at 4D Molecular Therapeutics, down from $494.7 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $625.0 million in Q2 2024 to a low of $247.8 million in Q3 2021.
- A 5-year average of $386.7 million and a median of $339.2 million in 2022 define the central range for Assets Average.
- Peak YoY movement for Assets Average: soared 109.55% in 2024, then fell 26.67% in 2025.
- 4D Molecular Therapeutics' Assets Average stood at $297.1 million in 2021, then fell by 8.77% to $271.0 million in 2022, then rose by 29.43% to $350.8 million in 2023, then surged by 65.99% to $582.2 million in 2024, then fell by 22.91% to $448.8 million in 2025.
- Per Business Quant, the three most recent readings for FDMT's Assets Average are $448.8 million (Q3 2025), $494.7 million (Q2 2025), and $538.1 million (Q1 2025).